Survivin-mediated Therapeutic Efficacy of Gemcitabine through Glucose-regulated Protein 78 in Hepatocellular Carcinoma

Glucose-Regulated Protein 78 (GRP78) Mediated the Efficacy to Curcumin Treatment on Hepatocellular Carcinoma

(2011) Yu-Jia Chang et al.   ANNALS OF SURGICAL ONCOLOGY

Survivin-Mediated Cancer Cell Migration Through GRP78 and Epithelial-Mesenchymal Transition (EMT) Marker Expression in Mahlavu Cells

(2011) Cheng-Jeng Tai et al.   ANNALS OF SURGICAL ONCOLOGY

MicroRNA Expression as a Predictive Marker for Gemcitabine Response after Surgical Resection of Pancreatic Cancer

(2011) Kenoki Ohuchida et al.   ANNALS OF SURGICAL ONCOLOGY

In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles

(2011) Brian R. Sloat et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Antisense Inhibition of Survivin Expression as a Cancer Therapeutic

(2011) R. A. Carrasco et al.   MOLECULAR CANCER THERAPEUTICS

Glucose-Regulated Protein 78 (GRP78) Silencing Enhances Cell Migration but Does Not Influence Cell Proliferation in Hepatocellular Carcinoma

(2010) Yu-Jia Chang et al.   ANNALS OF SURGICAL ONCOLOGY

Knockdown of Thrombomodulin Enhances HCC Cell Migration through Increase of ZEB1 and Decrease of E-cadherin Gene Expression

(2010) Ming-Te Huang et al.   ANNALS OF SURGICAL ONCOLOGY

Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma

(2010) Giuseppe Lombardi et al.   CANCER

Development of Molecularly Targeted Therapies in Hepatocellular Carcinoma: Where Do We Go Now?

(2010) R. S. Finn   CLINICAL CANCER RESEARCH

Targeting survivin in cancer: patent review

(2010) Jagat R Kanwar et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Knockdown of survivin expression by siRNAs enhances chemosensitivity of prostate cancer cells and attenuates its tumorigenicity

(2009) J. Shen et al.   ACTA BIOCHIMICA ET BIOPHYSICA SINICA

Glucose-Regulated Protein 78 Is a Novel Contributor to Acquisition of Resistance to Sorafenib in Hepatocellular Carcinoma

(2009) Jeng-Fong Chiou et al.   ANNALS OF SURGICAL ONCOLOGY

Overcoming Drug Resistance by Enhancing Apoptosis of Tumor Cells

(2009) Pepita Gimenez-Bonafe et al.   CURRENT CANCER DRUG TARGETS

Clinical pharmacology and pharmacogenetics of gemcitabine

(2009) Andrea Wong et al.   DRUG METABOLISM REVIEWS

Molecular targeted therapy for hepatocellular carcinoma

(2009) Melanie Thomas   JOURNAL OF GASTROENTEROLOGY

Gemcitabine and Arabinosylcytosin Pharmacogenomics: Genome-Wide Association and Drug Response Biomarkers

(2009) Liang Li et al.   PLoS One

Systemic therapy of hepatocellular carcinoma: Are we making progress?

(2008) Patricia Roxburgh et al.   ADVANCES IN THERAPY

Cancer Statistics, 2008

(2008) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma

(2008) Amani Asnacios et al.   CANCER

Membrane nanotubes physically connect T cells over long distances presenting a novel route for HIV-1 transmission

(2008) Stefanie Sowinski et al.   NATURE CELL BIOLOGY

Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors

(2008) Romano Danesi et al.   PHARMACOGENOMICS

Targeting the carbohydrates on HIV-1: Interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN

(2008) S.-K. Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA